Results

Picard Medical Inc.

11/16/2026 | Press release | Distributed by Public on 11/16/2026 16:33

Quarterly Report for Quarter Ending September 30, 2026 (Form 10-Q)

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following is a discussion and analysis of our financial condition and results of operations. The following should be read in conjunction with our financial statements and accompanying notes. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those projected, forecasted, or expected in these forward-looking statements as a result of various factors, including, but not limited to, those discussed below and elsewhere in this Form 10-Q. See "Cautionary Statement Regarding Forward-Looking Statements" in this report, and the risk factors set forth in Part I, Item 1A. Risk Factors in our Form 10-K, filed with the SEC on March 30, 2026.

Overview

PMI functions as a holding company and owns 100% of the membership interests of SynCardia. Business operations are carried out by and through SynCardia, and accordingly most of the information set forth in this Quarterly Report on Form 10-Q relates to the business of SynCardia. SynCardia is a medical technology company that manufactures and sells the only U.S. Food and Drug Administration ("FDA") and Health Canada approved SynCardia TAH, which fully replaces the function of a failing human heart. To date, more than 2,100 SynCardia TAHs have been implanted in patients across 27 countries, and the SynCardia TAH is an established bridge to heart transplantation for patients with biventricular heart failure, also referred to as end-stage heart failure, in the U.S. and around the globe. We are also pursuing additional research and advancements in medical technology, including the next-generation Emperor Total Artificial Heart ("Emperor TAH"), which is designed to combine the proven SynCardia TAH ventricles with the Company's next-generation electromechanical Emperor Drive System. The Emperor TAH is being developed as a platform to a fully implantable total artificial heart and eliminate the need for external drivers. The Emperor TAH is subject to additional development and regulatory review.

We continue development of the Emperor TAH program. In July 2026, we publicly presented the integrated architecture of the Emperor TAH platform at the 48th Annual International Conference of the IEEE Engineering in Medicine and Biology Society ("IEEE EMBC 2026"), providing the biomedical engineering community with a detailed view of the platform and its electromechanical drive architecture.

During the third quarter of 2026, preclinical and engineering development of the Emperor platform continued, including motor and control-system development, design optimization and bench testing. Early reliability testing of the Emperor drive system has exceeded 18 million operating cycles to date.

We also continue to pursue development of a next-generation pneumatic driver for the SynCardia TAH, with the objective of reducing costs, improving supply availability and supporting broader adoption of the SynCardia TAH.

The currently approved SynCardia TAH System consists of an implant including: (i) left and right artificial ventricles; (ii) external pneumatic drivers that power the implant; and (iii) drivelines that connect the external driver to the implant. The implantation procedure follows routine surgical techniques used by cardiothoracic surgeons performing heart transplantation. The system provides immediate and complete cardiac output by replacing both ventricles and all four heart valves. The SynCardia TAH is powered by pneumatic drivers available for in-hospital use, the Companion 2 Driver, and for in-home use, the Freedom Driver. These systems generate true pulsatile flow using a redundant pneumatic pump assembly, restoring full hemodynamics and giving patients time to stabilize, recover, and ultimately receive a heart transplant. Patients supported by the SynCardia TAH may be discharged from the hospital using the portable Freedom Driver.

Implantation of the SynCardia TAH is covered by the U.S. Centers for Medicare and Medicaid Services under National Coverage Determination 20.9.1 and is generally reimbursed under Diagnosis Related Group 001, the highest reimbursement category for cardiac procedures. Hospital reimbursement varies based on case complexity and institutional adjustments. Because reimbursement is determined primarily by the procedure rather than the specific device used, hospitals evaluate mechanical circulatory support technologies based on clinical suitability and overall cost effectiveness within the applicable reimbursement framework. We currently have SynCardia TAH inventory available to support near-term customer requirements.

Government Grant

In August 2026, the NIH/NHLBI awarded SynCardia Systems, LLC a SBIR Grant, Award No. 1R43HL184460-01, of up to $606,498 to support development of a wearable, mechanically actuated total artificial heart known as Emperor. The project and budget periods extend from September 1, 2026 through August 31, 2027. The authorized award amount is not the amount of income recognized or cash received.. In the three and nine months ended September 30, 2026, we recognized $0.1 million in Other Income from the SBIR Grant. As of November 12, 2026, we had recognized $0.2 million of grant funds as Other Income.

Loss of Controlled Company Status

Following the May 2026 Offering, Hunniwell no longer controls a majority of the voting power of the outstanding common stock of PMI, causing the Company to cease being a "controlled company" within the meaning of applicable rules of NYSE American. The Company is now subject to compliance with the independence requirements regarding board composition, compensation committee membership, and nominating committee membership. While PMI currently complies with all other corporate governance requirements of the NYSE American Company Guide, it will transition to a majority independent board by May 6, 2027, and expects to achieve full compliance within that deadline.


NYSE Notice

On May 8, 2026, the Company received a notice of noncompliance from NYSE Regulation (the "NYSE Notice") stating that it was not in compliance with Section 1003(a)(ii) of the NYSE American Company Guide (the "Company Guide") because it reported stockholders' equity of $3.8 million as of December 31, 2025 and net losses in three of its four most recent fiscal years (the "Stockholders' Equity Rule"). The Company timely submitted a plan of compliance (the "Compliance Plan") by the June 7, 2026 deadline. On July 22, 2026, the NYSE American notified the Company that it had accepted the Compliance Plan to regain compliance with Sections 1003(a)(i) and (ii) of the Company Guide, noting previously disclosed stockholders' equity of $3.8 million as of December 31, 2025 and a stockholders' deficit of $(1.4) million as of March 31, 2026.

The acceptance allows the Company to continue its listing on the NYSE American, subject to achieving the milestones in the Compliance Plan and quarterly NYSE American review, for a maximum of 18 months from the NYSE Notice, ending November 8, 2027. As of September 30, 2026, the Company reported stockholders' equity of $1.3 million.

Components of Our Results of Operations

Revenues

We generate revenue from the sale of our SynCardia TAH for patients, rental of Freedom Drivers, and from training and certification services, which are required before the first time a transplant center may deploy a SynCardia TAH. Revenue includes sales and services Centers located in the U.S. as well as Centers domiciled in foreign countries.

Cost of Revenues

Cost of revenues includes product costs, labor, overhead, inbound freight, and other product-related costs including excess inventory and obsolescence charges.

Research and Development

Research and development expenses include wages, stock-based compensation and benefits of employees performing research and development, and other operational costs related to our research and development activities, including facility-related expenses, allocation of corporate expenses, and external costs of outside contractors. While research and development supply expense are isolated by product, personnel are not. Research and development personnel do not work on current product production, therefore labor expense is not isolated by product.

Selling, General and Administrative

Selling, general and administrative expenses consist primarily of personnel-related expenses for executives, human resources, finance, and other general and administrative employees, including salary and stock-based compensation, professional services costs, and allocation of facility and overhead costs.

Our general and administrative expenses will increase in the future in connection with ongoing costs of operating as a public company, including expanding headcount and increased fees for directors and outside advisors. We expect to incur significant costs to comply with corporate governance, internal controls, and similar requirements applicable to public companies. Additionally, we expect to incur increased costs associated with establishing sales, marketing, and revenue growth.

Other Income (Expenses), net

Other income (expenses), net primarily consists of interest expense, changes in fair value of Senior secured note and Warrant liability, and Loss on settlement of debt.

Provision for Income Taxes

We are subject to U.S. federal and state income taxes and foreign taxes based on enacted rates, as adjusted for allowable credits, deductions, uncertain tax positions, changes in deferred tax assets, and liabilities and changes in tax laws. Provision for income taxes primarily relates to state income taxes.

Results of Operations

Comparison of Nine Months Ended September 30, 2026 and 2025

The following table summarizes Picard's results of operations (in thousands, except percentages) (unaudited):

​

​

Nine Months Ended September 30,

​

​

Change

​

​

​

2026

​

​

2025

​

​

$

​

​

%

​

Revenues, net:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Products

​

$

3,878

​

​

$

3,859

​

​

$

19

​

​

​

0

%

Rentals

​

​

443

​

​

​

72

​

​

​

371

​

​

​

515

%

Total revenues

​

4,321

​

​

3,931

​

​

390

​

​

​

10

%

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Cost of revenues:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Products

​

​

2,157

​

​

​

2,999

​

​

​

(842

)

​

​

-28

%

Rentals

​

​

1,178

​

​

​

1,547

​

​

​

(369

)

​

​

-24

%

Total cost of revenues

​

​

3,335

​

​

​

4,546

​

​

​

(1,211

)

​

​

-27

%

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Gross profit (loss)

​

​

986

​

​

​

(615

)

​

​

1,601

​

​

​

-260

%

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Operating expenses:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Research and development costs

​

​

3,590

​

​

​

2,502

​

​

​

1,088

​

​

​

43

%

Selling, general and administrative expenses

​

​

8,637

​

​

​

7,137

​

​

​

1,500

​

​

​

21

%

Total operating expenses, net

​

​

12,227

​

​

​

9,639

​

​

​

2,588

​

​

​

27

%

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Operating loss

​

​

(11,241

)

​

​

(10,254

)

​

​

(987

)

​

​

10

%

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Other income and expense:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Interest expense

​

​

(109

)

​

​

(5,386

)

​

​

5,277

​

​

​

-98

%

Derivative gain (loss)

​

​

-

​

​

​

(7,040

)

​

​

7,040

​

​

​

-100

%

Change in fair value of Senior secured note and Warrant liability

​

​

6,410

​

​

​

-

​

​

​

6,410​

​

​

​

100​

%

Loss on settlement of debt

​

​

(10,162

)

​

​

-

​

​

​

(10,162​

)

​

​

-100​

%

Loss on warrant exchange

​

​

(505

)

​

​

-

​

​

​

(505

)

​

​

-100

%

Other income

​

​

119

​

​

​

-

​

​

​

119

​

​

​

-100

%

Total other income (expenses), net

​

​

(4,247

)

​

​

(12,426

)

​

​

8,179

​

​

​

-66

%

Loss before income taxes

​

​

(15,488

)

​

​

(22,680

)

​

​

7,192

​

​

​

-32

%

Provision for income tax

​

​

(7)

​

​

​

(31

)

​

​

24

​

​

​

-77

%

Net loss

​

$

(15,495

)

​

$

(22,711

)

​

$

7,216

​

​

​

-32

%

Revenues

Total revenues increased by $0.4 million, or 10%, for the nine months ended September 30, 2026, as compared to the nine months ended September 30, 2025. This increase is due to an increase in U.S. rental sales of $0.4 million.

Cost of Revenues

Total cost of revenues decreased by $1.2 million, or 27%, for the nine months ended September 30, 2026, as compared to the nine months ended September 30, 2025. The decrease was primarily driven by improved gross margins on product sales, which more than offset the costs associated with rental sales. As a result, total cost of revenue decreased to 77% of total sales for the nine months ended September 30, 2026, compared with 116% for the corresponding period in 2025. This is due to improved finished goods inventory management between the periods.

Research and Development Expenses

Research and development expenses increased by $1.1 million, or 43%, for the nine months ended September 30, 2026, as compared to the nine months ended September 30, 2025. The increase was primarily attributable to increased activity and phase scheduling in of new product research. We do not track expenses by product candidate. While research and development supply expense are isolated by product, personnel are not. Research and Development personnel do not work on current product production, therefore labor expense is not isolated by product.

Selling, General and Administrative Expenses

Selling, general and administrative expenses increased by $1.5 million, or 21%, for the nine months ended September 30, 2026, as compared to the nine months ended September 30, 2025. The increase was primarily attributable to a $1.1 million increase in stock based compensation expenses, and $0.6 million of allocated labor cost, offset by $0.2 million in professional service fee reduction.

Total Other Income (Expenses)

Total other expenses decreased by $8.2 million, or 66%, for the nine months ended September 30, 2026, as compared to the nine months ended September 30, 2025. The decrease was primarily attributed to (i) the absence in 2026 of the $7.0 million Derivative loss recognized in 2025, (ii) a $5.3 million decrease in Interest expense, (iii) and a $6.4 million gain from Change fair value of the Senior secured note and Warrant liability, (iv) $0.1 million in SBIR grant revenue, and (v) $0.013 million in other income; offset by (i) a $10.2 million Loss on settlement of debt and (ii) a $0.5 million Loss on the warrant exchange.

Comparison of Three Months Ended September 30, 2026 and 2025

The following table summarizes Picard's results of operations (in thousands, except percentages) (unaudited):

Three Months Ended September 30,

Change

2026

2025

$

%

Revenues, net:

Products

$ - $ 1,115 $ (1,115

)

-100 %

Rentals

217 72 145 201 %

Total revenues

217 1,187 (970

)

-82 %

Cost of revenues:

Products

- 880 (880

)

-100 %

Rentals

122 437 (315

)

-72 %

Total cost of revenues

122 1,317 (1,195

)

-91 %

Gross profit (loss)

95 (130 ) 225 -173 %

Operating expenses:

Research and development costs

321 951 (630

)

-66 %

Selling, general and administrative expenses

1,875 2,406 (531

)

-22 %

Total operating expenses

2,196 3,357 (1,161

)

-35 %

Operating loss

(2,101 ) (3,487 ) 1,386 -40 %

Other income and expense:

Interest expense

(15 ) (2,404

)

2,389 -99 %

Derivative gain (loss)

- (4,535

)

4,535 -100 %

Change in fair value of Senior secured note and Warrant liability

669 - 669

100

%

Loss on settlement of debt

(878

)

- (878

)

-100

%

Other income

106 - 106 100 %

Total other income (expenses), net

(118

)

(6,939

)

6,821 -98 %

Loss before income taxes

(2,219 ) (10,426 ) 8,207 -79 %

Provision for income tax

- - - 0 %

Net loss

$ (2,219 ) $ (10,426 ) $ 8,207 -79 %

Revenues

Total revenues decreased by $1.0 million, or 82%, for the three months ended September 30, 2026, as compared to the three months ended September 30, 2025. This decrease was due to a decline in Product sales, offset by a $0.1 million increase in Rental sales. During the three months ended September 30, 2026, we recognized no Product sales revenue, compared to $1.1 million in the prior-year period. Rental revenues increased $0.1 million due to higher utilization of leased equipment.

The absence of Product sales resulted from our hospital customers having no eligible patients scheduled during the period, not from order cancellations, customer losses, or a known adverse trend or uncertainty in underlying demand. Based on preliminary results and confirmed orders as of November 12, 2026, we expect net product sales for the three months ending December 31, 2026, to exceed the $0.9 million we reported for the three months ended December 31, 2025, primarily due to orders received for TAHs. This forward-looking statement is subject to risks and uncertainties, including potential changes in customer delivery schedules, that could cause actual results to differ materially. See Cautionary Note Regarding Forward-Looking Statements and Part II, Item 1A, Risk Factors.

Cost of Revenues

Total cost of revenues decreased by $1.2 million, or 91%, for the three months ended September 30, 2026, as compared to the three months ended September 30, 2025. The decrease was mainly due to (i) a $0.9 million decrease in improved finished goods inventory management fees as we shift select manufacturing activities in-house, allowing us to utilize existing internal personnel and facilities more efficiently while also onboarding more cost-effective suppliers, and (ii) by a $0.3 million decrease in rental costs. We expect external expenditures to moderately increase in upcoming quarters as supplier transitions are finalized and development timelines resume.

Rental revenue and rental cost are not directly correlated. Rental revenue is earned when a patient is discharged from a hospital with a Freedom Driver and is recognized when it becomes likely that we will receive payment. Rental costs consist mainly of machine maintenance needed to maintain reliability and are incurred on a time schedule that depends on how long the driver is actually used; a single driver may serve multiple patients before maintenance service is required. Because the timing of usage and payment receipt generally does not correlate with the cost of service maintenance. Our total cost of revenue as a percentage of total sales for the three months ended September 30, 2026 and 2025 was 56% and 111%, respectively.

Research and Development Expenses

Research and development expenses decreased by $0.6 million, or 66%, for the three months ended September 30, 2026, as compared to the three months ended September 30, 2025. The decrease was primarily attributable to decreased activity and phase scheduling in of new product research. We do not track expenses by product candidate. While research and development supply expense are isolated by product, personnel are not. Research and Development personnel do not work on current product production, therefore labor expense is not isolated by product.

Selling, General and Administrative Expenses

Selling, general and administrative expenses decreased by $0.5 million, or 22%, for the three months ended September 30, 2026, as compared to the three months ended September 30, 2025. The decrease was primarily attributable to $0.5 million reduction in salary and wages.

Total Other Income (Expenses)

Total other expenses decreased by $6.8 million, or 98%, for the three months ended September 30, 2026, as compared to the three months ended September 30, 2025. The decrease was primarily attributable to (i) the absence in 2026 of the $4.5 million Derivative loss recognized in 2025, (ii) a $2.4 million decrease in Interest expense, and (iii) a $0.7 million gain from Change in fair value of the Senior secured note and Warrant liability, (iv) $0.1 million in SBIR grant revenue; partially offset by (i) a $0.9 million Loss on settlement of debt.

Liquidity and Capital Resources

Funding Requirements and Going Concern

We have incurred operating losses since inception, including net losses of $15.5 million and $22.7 million for the nine months ended September 30, 2026 and 2025, respectively. While we already have FDA-approved products that are generating commercial revenue, the business needs to scale up in order to offset a large, fixed overhead cost from our site in Tucson, Arizona. Moreover, we are also investing heavily in the development of updates and next generation devices; therefore, we expect to continue to incur significant expenses and operating losses for the foreseeable future. Furthermore, we expect to incur additional expenses with operating as a public company.

Until such time as we can sufficiently grow product and rental revenue, we expect to finance our cash needs through a combination of equity and debt financing, or other capital sources, including related parties. To the extent that we raise additional capital through the future sale of equity or debt, the ownership interest of our stockholders will be diluted. The terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing common stockholders. If we are unable to raise sufficient funds through equity or debt financing, we may be required to delay, limit, curtail or terminate our product development or future growth efforts. Additionally, we may never become profitable, or if we do, may not be able to sustain profitability on a recurring basis.

We have considered that our long-term operations anticipate continuing net losses and the need for potential debt or equity financing. However, there can be no assurances that additional funding or other sources of capital will be available on terms acceptable to us, or at all. If additional capital is not secured when required, we may need to delay or curtail our operations until such funding is received. If we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, financial condition and results of operations could be materially adversely affected. As a result of these conditions, we have concluded that there is substantial doubt over our ability to continue as a going concern as conditions and events, considered in the aggregate, indicate it is probable we will be unable to meet our obligations as they become due within one year after the date that the financial statements included in this filing are issued. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities and commitments in the normal course of business. The financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern. Our ability to continue as a going concern is dependent upon our ability to increase sales and raise additional funds and financing. Our future capital requirements and the adequacy of available funds will depend on many factors, including those set forth in Part I, Item 1A. Risk Factors of our Form 10-K filed March 30, 2026.

Sources of Liquidity

To date, we have funded our operations primarily with proceeds from our Series A-1 Preferred Stock, loans from related parties, convertible notes, and sales of common stock or loans from other investors. We completed our Initial Public Offering in September 2025. In December 2025, we entered into a Securities Purchase Agreement under which we issued a $15.0 million Senior Secured Note due 2028, with the right to issue up to an additional $35.0 million in subsequent closings.

In May 2026, we completed the May 2026 Offering of 333,333 shares of common stock (or pre-funded warrants in lieu thereof for certain purchasers), Series A Common Warrants for up to 333,333 shares, and Series B Common Warrants for up to 333,333 shares, at a combined price of $15.0 per share, for gross proceeds of $5.0 million. Net proceeds were $3.1 million after $0.9 million of offering costs and $1.0 million applied in a cashless transaction to settle Senior Secured Note principal. We also used net proceeds to repay in full the Fannet, Anchor, and Quick Capital Notes.

The unpaid principal of the Senior Secured Note decreased from $15.0 million to no principal remaining outstanding as of September 30, 2026, through cash repayments and share settlements.

During 2026, we also obtained approximately $3.6 million of loans and convertible notes: $1.2 million from affiliates of related parties (FFF-II and Fang Family Fund, LLC), $0.6 million from three other lenders (Fannet Technologies, Inc., Anchor Investment, LLC and BioVanta Investment LLC), and $1.8 million of convertible notes, of which $0.3 million converted into 84,045 shares of common stock in August 2026. The Fannet and Anchor loans were repaid in full as described above. The FFF- II, Fang Family Fund, LLC, and the BioVanta Investment LLC notes bear interest at 0% to 6% and are due between February and September 2027, or earlier upon our receipt of external funding. The FFF II and Fang Family Fund loans become due on payment terms to be determined if we do not receive at least $1.0 million of external funding within two months of the deposit date. The BioVanta loan becomes due in six months from issuance if we do not receive at least $2.0 million of external funding within two months of the deposit date. See notes to our unaudited condensed consolidated financial statements for details.

On November 04, 2026, the Company, through SynCardia Systems, LLC, entered into a development and manufacturing agreement for the Freedom Driver System requiring aggregate development payments of $0.5 million payable upon specified milestones. The initial $0.2 million payment had not been made as of the date of this Quarterly Report. The Company expects to fund these obligations from available cash resources and additional financing, as available.

Cash Flows

The following table shows a summary of our cash flows (in thousands):

Nine Months Ended September 30,

2026

2025

Net cash used in operating activities

$ (7,148 ) $ (11,296 )

Net cash used in investing activities

$ (26

)

$ -

Net cash provided by (used in) financing activities

$ (4,249 ) $ 14,061

Net cash used in operating activities

Net cash used in operating activities of $7.1 million for the nine months ended September 30, 2026 was primarily attributable to (i) a $15.5 million Net loss, (ii) a $6.4 million non-cash gain from Change in fair value of the Senior secured note and Warrant liability and (iii) $0.1 million increase in government grant receivable; offset by (i) a $10.2 million non-cash Loss on settlement of debt, (ii) $1.5 million net change in working capital, (iii) $1.6 million in Stock-based compensation, (iv) $0.5 million non-cash Loss on the warrant exchange, (v) $0.1 million in depreciation and amortization, (vi) $0.7 million increase in Provision of excess and obsolete inventory, and (vii) $0.3 million in amortization of right-of- use asset.

Net cash used in operating activities of $11.3 million for the nine months ended September 30, 2025, was primarily attributable to a $22.7 million Net loss; and $1.7 million net change in working capital; offset by (i) $11.6 million in Derivative loss and Amortization of discount on debt issued, (ii) $0.6 million increase in Provision for excess and obsolete inventory, (iii) a $0.5 million increase in Stock-based compensation, (iv) $0.1 million depreciation and amortization and (v) a $0.3.million increase in Amortization of right of use assets.

Net cash used in investing activities

Net cash used in investing activities was $0.03 million and $0 million for the nine months ended September 30, 2026 and 2025, respectively.

Net cash provided by (used in) financing activities

Net cash used in financing activities was $4.2 million for the nine months ended September 30, 2026, primarily consisting of (i) repayment of $9.5 million in notes payable and (ii) $0.06 million Repayments of finance lease obligations; (iii) $0.6 million of repayments of convertible note to third party; offset by (i) $0.3 million of Proceeds from loans from related party, net of repayments, (ii) a $0.06 million of Stock option exercise, (iii) $3.1 million of Proceeds from issuance of common stock and warrants, (iv) $0.6 million of proceeds from issuance of short term notes; and (v) $1.8 million of proceeds from issuance of convertible notes to third party.

Net cash provided by financing activities was $14.1 million for the nine months ended September 30, 2025, which primarily consisted of net proceeds of $15.2 million, $2.0 million, $2.2 million, and $2.9 million from the issuance of common stock, convertible notes, stock subscriptions, and related party notes, respectively, offset by $8.2 million in repayments of related party loan notes.

Off-Balance Sheet Arrangements

As of September 30, 2026 and December 31, 2025, we had no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources.

Critical Accounting Policies and Estimates

Management's discussion and analysis of financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires our management to make judgments, assumptions and estimates that affect the reported amounts of assets, liabilities, revenues, and expenses, and related disclosure of contingent assets and liabilities. We evaluate these judgments, assumptions and estimates for changes that would affect the reported amounts. These estimates are based on management's historical industry experience and on various other judgments and assumptions that are believed to be reasonable under the circumstances. Actual results may differ from these judgments, assumptions and estimates. A discussion of recent accounting pronouncements and our significant accounting policies, including further discussion of the accounting policies described below, can be found in Note 2 "Summary of Significant Accounting Policies" to our condensed consolidated financial statements included in this quarterly report. None of those policies are deemed to be critical accounting policies nor critical accounting estimates.

China Distribution Agreement

In October 2026, we notified SynCardia Beijing, our exclusive distributor in mainland China, Hong Kong, Macau and Taiwan, that we are terminating our distribution and registration services agreements effective December 15, 2026, and we no longer intend to make the investment described in Note 7. After that date, we will no longer sell through SynCardia Beijing. We are evaluating the effect on our net product sales and results of operations and cannot reasonably estimate it at this time. Continued sales in these territories will depend on our ability to establish alternative distribution and maintain product registrations. See Part II, Item 1A, Risk Factors.

Emerging Growth Company Status

Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 13(a) of the Exchange Act for complying with new or revised accounting standards applicable to public companies. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of this extended transition period. As a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates for such new or revised standards. We may elect to comply with public company effective dates at any time, and such election would be irrevocable pursuant to Section 107(b) of the JOBS Act.

We are also a "smaller reporting company" as defined in Regulation S-K under the Securities Act and may elect to take advantage of certain of the scaled disclosures available to smaller reporting companies. We may be a smaller reporting company even after we are no longer an "emerging growth company."

Picard Medical Inc. published this content on November 16, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on November 16, 2026 at 22:33 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]